BDRX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2019Q4

-20000.000

-98.82%

Estimates Revision

The market is revising No Change the revenue expectations for Biodexa Pharmaceuticals Plc (BDRX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -4.41%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-4.41%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Biodexa Pharmaceuticals PLC (BDRX.O) is -19.44, compared to its 5-year average forward P/E of -52.90. For a more detailed relative valuation and DCF analysis to assess Biodexa Pharmaceuticals PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-52.90

Current PE

-19.44

Overvalued PE

126.63

Undervalued PE

-232.44

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.31

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.46

Undervalued EV/EBITDA

-4.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

45.39

Current PS

0.00

Overvalued PS

134.18

Undervalued PS

-43.40

Financials

Annual

Quarterly

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

BDRX News & Events

Events Timeline

No data

News

9.5

12-16Benzinga

B. Riley Financial Shares Surge Approximately 25%; Check Out 20 Stocks Making Moves in Premarket Trading

9.5

12-09Benzinga

Mama's Creations Stock Rises Over 13%; Check Out 20 Stocks Making Moves in Premarket Trading

2.0

11-24Newsfilter

Biodexa Activates First European Site for Phase 3 Serenta Trial in FAP

People Also Watch

Frequently Asked Questions

What is Biodexa Pharmaceuticals PLC (BDRX) stock price today?

The current price of BDRX is 6.5 USD — it has increased 35.98 % in the last trading day.

What is Biodexa Pharmaceuticals PLC (BDRX)'s business?

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.

What is the price predicton of BDRX Stock?

Wall Street analysts forecast BDRX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDRX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Biodexa Pharmaceuticals PLC (BDRX)'s revenue for the last quarter?

Biodexa Pharmaceuticals PLC revenue for the last quarter amounts to NaN USD, decreased % YoY.

What is Biodexa Pharmaceuticals PLC (BDRX)'s earnings per share (EPS) for the last quarter?

Biodexa Pharmaceuticals PLC. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for Biodexa Pharmaceuticals PLC (BDRX)'s fundamentals?

How many employees does Biodexa Pharmaceuticals PLC (BDRX). have?

Biodexa Pharmaceuticals PLC (BDRX) has 16 emplpoyees as of December 17 2025.

What is Biodexa Pharmaceuticals PLC (BDRX) market cap?

Today BDRX has the market capitalization of 4.51M USD.